Sequence-encoded quantitative invader assay enables highly sensitive hepatitis B virus DNA quantification in a single tube without the use of a calibration curve

The Analyst ◽  
2019 ◽  
Vol 144 (19) ◽  
pp. 5775-5784 ◽  
Author(s):  
Nan Sheng ◽  
Bingjie Zou ◽  
Huan Tong ◽  
Yan Lu ◽  
Sixi Xing ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Calibration Curve ◽  
Absolute Quantification ◽  
Hbv Dna ◽  
Single Tube ◽  
Hepatitis B Virus Dna ◽  
Invader Assay ◽  
Highly Sensitive ◽  
B Virus

Absolute quantification of HBV-DNA by sequence-encoded Quantitative Invader assay in a single tube without using calibration curves.

Hepatitis B virus DNA quantification with the three-in-one (3io) method allows accurate single-step differentiation of total HBV DNA and cccDNA in biopsy-size liver samples

2014 ◽  
Vol 60 (4) ◽  
pp. 354-360 ◽  
Author(s):  
Andrzej Taranta ◽  
Bui Tien Sy ◽  
Behrend Johan Zacher ◽  
Magdalena Rogalska-Taranta ◽  
Michael Peter Manns ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Hbv Dna ◽  
Dna Quantification ◽  
Single Step ◽  
Hepatitis B Virus Dna ◽  
B Virus

scholarly journals Clinical significance of hepatitis B virus DNA (HBV-DNA) assay in sera of HBsAg carriers.

Kanzo ◽  
1985 ◽  
Vol 26 (10) ◽  
pp. 1307-1314
Author(s):  
Takeshi SODEYAMA ◽  
Kendo KIYOSAWA ◽  
Shuichi WADA ◽  
Makoto NAKAMURA ◽  
Hidetoshi YODA ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Clinical Significance ◽  
Hbv Dna ◽  
Hepatitis B Virus Dna ◽  
Dna Assay ◽  
Hbsag Carriers ◽  
B Virus

scholarly journals STUDI PERBANDINGAN PEMAKAIAN PRIMER HBS1 DAN HBS2 DENGAN PRIMER P7 DAN P8 DALAM DETEKSI DNA VIRUS HEPATITIS B PADA PENDONOR DARAH

2020 ◽  
Vol 7 (2) ◽  
pp. 73
Author(s):  
Supiana Dian Nurtjahyani ◽  
Mohammad Amin ◽  
Retno Handajan
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Blood Donors ◽  
Hbv Dna ◽  
Chain Reaction ◽  
Hepatitis B Virus Dna ◽  
Serological Examination ◽  
B Virus ◽  
The Right ◽  
Test Result

<p><em>Examination of the hepatitis B virus as a disease of hepatitis serologically has been carried out a lot, but this serological examination can experience problems if there is a low window period, so even though a negative test result is still possible in a patient's body infected with the hepatitis B virus, a fast and accurate examination is needed. PCR examination is an alternative solution to overcome this problem because the results are more accurate and valid because it can directly detect hepatitis B virus DNA as the cause of hepatitis B infection. This examination requires selecting the right primer so that accurate results are obtained. The aim of this study was to compare the use of HBS1 and HBS2 primers with P7 and P8 primers in the detection of Hepatitis B virus DNA in blood donors. The method used in this study is a laboratory experiment with Polymeration Chain Reaction (PCR) examination. The results showed that the HBS1 and HBS2 primers produced more positive HBV DNA by 76.92% compared to P7 and P8 primers, only 23.08%. Conclusion HBS1 and HBS2 primers can detect positive HBV DNA with more results.</em><em></em></p>

scholarly journals Early Viral Kinetics of Telbivudine and Entecavir: Results of a 12-Week Randomized Exploratory Study with Patients with HBeAg-Positive Chronic Hepatitis B

2009 ◽  
Vol 54 (3) ◽  
pp. 1242-1247 ◽  
Author(s):  
Dong Jin Suh ◽  
Soon Ho Um ◽  
Eva Herrmann ◽  
Ju-Hyun Kim ◽  
Young Sok Lee ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Alanine Aminotransferase ◽  
Hbv Dna ◽  
Viral Production ◽  
Viral Kinetics ◽  
Hepatitis B Virus Dna ◽  
B Virus ◽  
Infected Cells ◽  
Early Viral Kinetics

ABSTRACT We characterized the early viral kinetic profiles of telbivudine and entecavir and the effects of these potent nucleoside analogs on hepatitis B virus (HBV) DNA and alanine aminotransferase levels in adults with hepatitis B e antigen-positive compensated chronic hepatitis B. Forty-four patients were enrolled in this open-label, parallel-group, multicenter study and randomized to receive telbivudine or entecavir for 12 weeks. Reductions in hepatitis B virus DNA and alanine aminotransferase levels from baseline to weeks 2, 4, 8, and 12 were assessed. Viral kinetic parameters, including viral clearance per day, loss of infected cells per day, and efficiency of inhibition of viral production, were estimated by using a biphasic mathematical model. Statistical analyses were limited to descriptive analyses. The 2 treatment groups achieved similar reductions in HBV DNA and alanine aminotransferase levels. Mean reductions in levels of hepatitis B virus DNA at week 12 were 6.6 ± 1.6 and 6.5 ± 1.5 log10 copies/ml for the telbivudine- and entecavir-treated patients, respectively. There were no significant differences between groups in values for mean viral clearance per day, mean loss of infected cells per day, or efficiency of blocking viral production. The safety profiles for both medications were favorable. During the first 12 weeks of treatment, telbivudine and entecavir demonstrated similar antiviral potencies, resulting in a rapid and profound suppression of serum hepatitis B virus DNA and reduction of alanine aminotransferase levels. No differences in the effects of these 2 agents on early viral kinetics were observed. Both medications were well tolerated.

scholarly journals Investigation of Hepatitis B virus DNA among HBsAg positive patients in Kabul, Afghanistan

2021 ◽  
Vol 8 ◽  
Author(s):  
Hashmatullah Yousufi ◽  
Ahmad Zia Noori ◽  
Hamidullah Rasekh
Keyword(s):  
Risk Factors ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Hbv Dna ◽  
Age Group ◽  
Dna Testing ◽  
Viral Dna ◽  
Hepatitis B Virus Dna ◽  
B Virus ◽  
Hepatitis B Treatment

Background: Hepatitis B virus (HBV) infections are one of the world's health problems that annually kill about 500,000 to 1,200,000 people. Investigation of HBV DNA in the person infected with HBV is a definitive indicator of activation and replication of HBV.Objectives: The aim of this study is to investigate the DNA of HBV in HBsAg positive patients and to study the risk factors for virus activation. Methods: This study was conducted on 106 HBsAg positive patients from January 2020 to July 2020 in Kabul. After informed consent, 3 to 5 milliliters of blood was collected for the HBV-DNA testing using the Real-time PCR method.Result: Out of 106 HbsAg positive patients, 74 (69.8%) were males and 32 (30.2%) females. The patients were aged between 11 and 65 years. Hepatitis B virus DNA was positive in 58 (54.7%) of the samples, 41 (70.7%) were male and 17 (29.3%) were female. The viral DNA load was in the range of 9.85 x 102 to 9.3 x 108 copies/ ml. Most of the patients were aged between 20 and 30 years. Conclusion: From 106 HbsAg positive patients, 23(39.7%) were in the age group of 20 – 30 years, and males were more infected than females. The majority of the patients were married and had an informal job with education below grade 12. No specific differences were found in the availability of HBV DNA between patients who received hepatitis B treatment before and those who did not.    

scholarly journals Hepatitis B seroconversion revisited: new insights into the natural history of acute hepatitis B virus (HBV) infection from quantitative and highly sensitive assays and novel biomarkers

2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Mary C. Kuhns ◽  
Vera Holzmayer ◽  
Anne L. McNamara ◽  
Mark Anderson ◽  
Gavin A. Cloherty
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Acute Hepatitis ◽  
Quantitative Research ◽  
Hepatitis B Surface Antigen ◽  
Serum Markers ◽  
Hbv Dna ◽  
Highly Sensitive ◽  
B Virus ◽  
Acute Hepatitis B

Abstract Background Hepatitis B virus (HBV) serum markers during typical acute self-limited infection are usually depicted as a composite of traditional HBV markers. The current study updates and expands our knowledge of acute hepatitis B with quantitative molecular and serological data on longitudinal samples from five plasmapheresis donors with acute HBV. Methods 137 longitudinal samples from five plasmapheresis donors with acute HBV were tested, four with self-limited infection and one who developed persistent infection. Testing included quantitative hepatitis B surface antigen (HBsAg), antibodies to HBV antigens, quantitative HBV e antigen (HBeAg), HBV DNA, quantitative HBV core-related antigen (HBcrAg), the highly sensitive ARCHITECT HBsAg NEXT (HBsAgNx) assay, and a quantitative research assay for HBV pregenomic RNA (pg RNA). Results Peak levels of HBV DNA and HBsAg differed by several orders of magnitude among the panels (2.2 × 105–2.7 × 109 IU/ml for HBV DNA and 7.9–1.1 × 105 IU/ml for HBsAg). HBsAg levels peaked an average of 2.8 days after the HBV DNA peak. The overall duration of observed HBsAg positivity was increased by the more sensitive HBsAgNx assay compared to the quantitative assay in four panels. Intermittently detectable low-level HBV DNA was observed after HBsAg loss in three panels. Peak HBeAg levels occurred 2–20 days after the DNA peak and ranged from 1.1 to 4.5 × 103 IU/ml. In four panels with resolution of infection, anti-HBs levels indicating immunity (≥ 10 mIU/ml) were detected 19–317 days after the HBV DNA peak. Maximum HBcrAg concentrations ranged from 1 × 105 to > 6.4 × 106 U/ml and correlated with HBeAg values (R2 = 0.9495) and with HBV DNA values (R2 = 0.8828). Peak pgRNA values ranged from 1.6 × 103 to 1.4 × 108 U/ml and correlated with HBV DNA (R2 = 0.9013). Conclusion Traditional and new/novel HBV biomarkers were used to generate molecular and serological profiles for seroconversion panels spanning the early to late phases of acute HBV. Seroconversion profiles were heterogeneous and may be instructive in appreciating the spectrum of acute profiles relative to the typical composite representation.

scholarly journals Hepatitis B virus DNA (HBV-DNA) in anti-HBe positive sera

2008 ◽  
Vol 4 (3) ◽  
pp. 177-183 ◽  
Author(s):  
Francesco Negro ◽  
Elisabetta Chiaberge ◽  
Salvatore Oliviero ◽  
Marlene Hammer ◽  
Mark Berninger ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Hbv Dna ◽  
Hepatitis B Virus Dna ◽  
B Virus
Sign in / Sign up

Export Citation Format

Share Document